• Explore /
  • Poster
  • / Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.

Abstract Video & Slides Poster

Authors

null

Jonathan W. Riess

University of California Davis Comprehensive Cancer Center, Sacramento, CA

Jonathan W. Riess , Mark D. Krailo , Sukhmani Kaur Padda , Susan G. Groshen , Heather A. Wakelee , Karen L. Reckamp , Marianna Koczywas , Zofia Piotrowska , Conor Ernst Steuer , Chul Kim , Cloud P. Paweletz , Lynette M. Sholl , Grace Heavey , Jill Kolesar , Jeffrey Moscow , Pasi A. Janne , Primo "Lucky" N. Lara Jr., Edward M. Newman , David R. Gandara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02496663

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9014)

DOI

10.1200/JCO.2022.40.16_suppl.9014

Abstract #

9014

Poster Bd #

2

Abstract Disclosures

Similar Posters

First Author: Jonathan W. Riess

First Author: Jan Alexander Stratmann

First Author: Shen Zhao

First Author: Daniel Shao-Weng Tan